Prices
Novo Nordisk’s CagriSema Weight Loss Drug Trial Results Disappoint Investors
CagriSema, weight loss, clinical trial, Novo Nordisk, stock price drop, obesity treatment
Drug Pricing and the Uncertain Future of the IRA Under Trump
IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices
Novo Nordisk Slashes Wegovy Price for Cash-Paying Patients
Wegovy, price cut, Novo Nordisk, NovoCare Pharmacy, obesity treatment, semaglutide, direct-to-patient, cash-paying patients
Praxis Precision Medicines Faces Setback in Essential Tremor Drug Trial
Praxis Precision Medicines, ulixacaltamide, essential tremor, clinical trial failure, stock price drop
Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff
Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda
Eli Lilly Acquires Organovo’s FXR Program for $10M, Triggering 244% Stock Surge
Eli Lilly, Organovo, FXR program, FXR314, acquisition, inflammatory bowel disease (IBD), stock price increase
Eli Lilly makes Zepbound vials cheaper for self-paying patients
self-paying, Eli, Eli Lilly, Prices, Monthly (qualifier value), Dosage, 7.5 mg, 10 mg
Lilly lowers price of Zepbound vials, launches new doses
Eli Lilly, Dosage, Prices, Affordability, Obesity
AnaptysBio’s Rosnilimab Shows Promising Results in Phase 2b Rheumatoid Arthritis Trial, Driving Stock Surge
AnaptysBio, rosnilimab, rheumatoid arthritis, Phase 2b trial, RENOIR study, clinical efficacy, stock price increase, immunology therapeutics
AstraZeneca Shares Rise as China Investigation Impact Appears Limited
AstraZeneca, China investigation, share price, financial performance, import taxes, investor confidence